Functional demands on a bioartificial liver support (BAL) device are not limited to biosynthetic activities, but must also encompass metabolic removal of potentially toxic substances. For most BALs, however, the concept and design are exclusively directed to biosynthetic support. To add the ability to metabolize and remove toxic substances, we designed a double-compartment cell culture apparatus (DCCA). Two compartments are separated from each other by a compact epithelial cell sheet spread over a synthetic microporous membrane. When a renal proximal convoluted tubular cell line that had been transduced with the human multidrug-resistant (MDR) gene, PCTL-MDR, was introduced into one of the compartments (hereafter referred to as the "inner" compartment) of the DCCA, a compact cellular monolayer was formed on the membrane. Ammonium ions passed across the membrane, but glucose and its metabolite lactate could not, indicating that the DCCA allowed selective transportation of cellular metabolites. In addition to PCTL-MDR, HepG2, a cell line of hepatic-origin, transduced with CYP3A4 (designated GS-3A4-HepG2), was seeded on the opposite side of the membrane, and the metabolism and transportation of lidocaine were studied. The lidocaine metabolite, monoethylglycinexylidide, was detected in the inner compartment across the PCTL-MDR cell layered membrane, indicating that metabolism and the selective transportation of metabolites between the two compartments occurred by cooperation of renal and hepatic cells. These results suggest that this type of DCCA represents a novel BAL that possesses biotransporting activities, as well as biosynthetic and metabolic activities.
INTRODUCTION
A typical type of BAL is composed of a hollow fiber module in which hepatocytes are packed either outside or inside the hollow fiber tubules, and the patient's Progress in modern biotechnology and medicine enables artificial devices to support patients at the end plasma or blood interacts with the cells through the hollow fiber membrane (4, 16 ). In another model, hepato-stage of organ failure (12, 17) . One major application of these devices is the support of liver function. There are cytes are cultured on support matrices such as small beads or membranes, and patient plasma is applied di-two concepts in extracorporeal artificial liver support: the nonbiological approach or the cell-based hybrid ap-rectly (2, 11, 15) . Previously, we developed a BAL of fixed bed perfusion reactor type, which essentially belongs to proach. The former has been developed as plasmapheresis (9) and the latter as bioartificial liver support (BAL) the latter model, and succeeded in extending the survival time of pigs with ischemic liver failure (7). (2, 16) . Over the past few years, some cell-based BALs succeeded in providing life support for patients with ful-
The above two BAL models carry out hepatic biosynthesis and metabolism, but cannot actively transport toxic minant hepatic failure waiting for liver transplantation (2, 4, 13, 16) . Moreover, temporary support with a BAL substances. During the development of our BAL, we noticed that hepatocytes alone are not sufficient for achiev-may allow time for the patient's own liver to regenerate without need for transplantation.
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hepatocytes, we chose a cell line of kidney proximal Flow Control and Membrane Permeability Test convoluted tubule origin, PCTL-MDR, to perform me-After DCCA assembly, a solution of 0.15 mol/L tabolism and active transportation tests. The cell line, NaCl was constantly circulated at the rate of 10 ml/min. PTCL, was first established from rabbit kidney proximal To visualize medium flow, 1 ml of blue dextran (10 mg/ cells by transduction of SV40T antigen, and further ml, Sigma) was added directly to the circulation medium transduced with multidrug-resistant (MDR) gene to inthrough the inlet tube. crease anion transport activity, and therefore termed
To determine the diffusion rate of small molecules PCTL-MDR (19) . In a small-scale experiment, the monoacross the cell-free ePTFE membrane in the DCCA, a layer membrane of PTCL cells successfully transported test solution (0.15 mol/L NaCl containing either 0.2 a model toxic substrate, digoxin, and hydroxytestostermol/L calcium lactate, 1.0 mmol/L ammonium sulfate, one, which was produced by recombinant HepG2 (5,6). or 17.5 mmol/L glucose) was circulated in one of the To develop a preclinical scale module that is applicable two circuits at the rate of 10 ml/min. NaCl solution flow for experimental animals such as rabbits and pigs, we in the other compartment was at the same rate and samdesigned and constructed a double-compartment cell culples were collected from each reservoir at 4-h intervals. ture apparatus (DCCA) with a membrane separating the Time-dependent change of lactate concentration was detwo compartments on which actively transporting cells termined using Lactate Pro Test Strip (ARKRAY Inc, are layered. This communication describes the construc-Kyoto, Japan), that of ammonium ion concentration by tion and functional characteristics of such a DCCA and using an AMICHECK Meter (ARKRAY Inc), and of discusses prospects for use of this novel module design.
glucose concentration using the anthrone-sulfuric acid method (3). Diffusion rates for lactate, ammonium, and MATERIALS AND METHODS glucose were calculated from these values.
Brief Description of the Double-Compartment Cell Cell Culture Experiments Culture Apparatus (DCCA) and Circulation System
The body of the DCCA consists of a pair of 5-mm-Before inoculation into the apparatus, cells were grown in 175-cm 2 culture flasks with a mixture (1:1) of thick glass plates (150 × 250 mm) and a pair of sizematched 3-mm-thick silicon molds with a square win-Dulbecco's modified Eagle's medium and Ham's nutrient mixture F-12 (DMEM/F12 medium, Invitrogen, dow (110 × 210 mm) as shown in Figure 1 . Expanded polytetrafluoro-ethylene (ePTFE) microporous mem-Carlsbad, CA, USA), supplemented with 5% fetal bovine serum (Invitrogen). GS-3A4-HepG2 and PCTL-brane (Fluoropore, FP100, Sumitomo Electric Industry, Osaka, Japan) was set between the two silicon molds so MDR cells were cultured in the presence of 200 µg/ml Zeocin TM (R250-01, Invitrogen), or 40 µg/ml neomycin that it divided the inner space into two compartments in the middle. The average pore size of the ePTFE mem-(Sigma, St. Louis, MO, USA), respectively. Cells at the subconfluent stage were harvested with 0.25% trypsin brane was 1 µm and thickness of 75 µm. There was a conformable zigzag flow pass (32.5 mm width) in each (15090-046, Invitrogen) for inoculation. The sterilized DCCA was first filled with 95% etha-compartment. The volume and area of flow pass were 64.5 cm 3 and 215 cm 2 , respectively. These components nol to remove micro air bubbles in the ePTFE membrane. It was washed with phosphate-buffered saline and (i.e., glass plates, silicon molds, and an ePTFE membrane) were held tightly together in aluminum frames then filled with DMEM/F12 culture medium containing 5% fetal bovine serum. with clamps to form the DCCA. For autoclaving, they were put together loosely, and tightened after cooling.
Two different cell lines were inoculated successively on the opposite sides of the ePTFE membrane in a The DCCA possesses a pair of outlets and inlets for each compartment (Fig. 2) . Medium is circulated inde-DCCA placed horizontally. First, 1.0 × 10 8 kidneyderived PCTL-MDR cells in 100 ml were introduced pendently through each compartment by way of separate reservoir bottles (500 ml each), using a peristaltic pump into one side of the compartment through the circulation system using a peristaltic pump. After the inoculation, (Master Flex L/S 7520-10) with a 7012-20 type pump head (Cole-Parmer Ins., IL, USA). Reservoir bottles the apparatus was gently shaken for 5 min to allow the cells to spread evenly over the membrane. The apparatus were supplied with 5% CO 2 /95% O 2 gas continuously to adjust medium pH to 7.2. Each circulation line has a cell was kept static for 1 h and medium circulation started at a flow rate of 1 ml/min for 3 h. The circulation rate was inoculation port and two air-trap chambers. The entire system, including reservoir bottles, can be placed in an raised to 5 ml/min for an additional 21 h. Next, the DCCA was turned upside down, and 1.0 × 10 8 GS-3A4-incubator at 37°C. DCCA were placed vertically to avoid accumulation of air bubbles, except at the time of HepG2 cells were inoculated into the other compartment using the same procedure as for PCTL-MDR. Circula-cell inoculation. tion of medium on the PCTL-MDR side was stopped tively. According to preliminary experiments, 1.0 × 10 8 cells of PTCL-MDR reached confluence after 3 days of during the second inoculation. Twenty-four hours thereafter, the apparatus was placed vertically and medium incubation.
During the culture period, unless otherwise stated, a flow started on both sides (5 ml/min). Hereafter, the ePTFE membrane side on which PCTL-MDR cells were medium reservoir bottle was changed every other day and a new bottle with 500 ml fresh medium substituted. attached is referred to as the outer side, and the other side on which GS-3A4-HepG2 cells were attached as Samples (5 ml) were taken from the two reservoir bottles at the times indicated, and stored frozen at −20°C the inner side. Concomitantly, the compartment and the circulation of the outer side is referred to as the outer until HPLC analysis. In some experiments, lidocaine (final concentraton, 100 µmol/L) (Alexis Biochemicals, compartment and outer circuit, and those of the inner side as the inner compartment and inner circuit, respec-Montreal, Canada) was added as a test substance to in- vestigate its metabolism and transportation across the membrane.
HPLC Analysis
Lidocaine and its metabolites in the culture medium were analyzed by a C18 reverse-phase column (particle size 5 µm, internal diameter 4.6 × 150 mm) (Inertsil ODS-3V, GL Sciences, Tokyo, Japan), using an HPLC system (Model 805, Waters, MA, USA). Prior to HPLC analysis, 2 ml of the medium was partially purified with a Sep-Pak Plus (Waters Corp., Milford, MA, USA), and 25 µl of the sample thus obtained applied to the column. Samples were eluted with 15% acetonitrile in 20 mmol/ L NaClO 4 solution (pH 2.5) at a flow rate of 2.0 ml/min at 40°C, and lidocaine and its metabolites detected at a wavelength of 205 nm (Type L-4000 UV detector, Hitachi, Tokyo, Japan). The authentic standard of lidocaine major metabolite, monoethylglycinexylidide (MEGX), was a generous gift from Astra Pharmaceuticals (Wayne, PA, USA).
RESULTS

Examination of Medium Flow
After the initial DCCA conception and design, several prototypes were constructed and tested. Improvements were mainly carried out on the shape of flow pass to remove air bubbles and to smooth medium flow. To remove air bubbles, inlet and outlet ports were changed 3A). Although medium still flowed slightly faster in the middle of the stream, no dead space was now seen at any place in the compartment (Fig. 3B ).
Passive Diffusion Across Cell-Free Membranes
mined every 12 h for the subsequent 7 days of constant circulation. The initial concentrations of lactate ions in As shown in Figure 4 , the concentration of lactate both compartments were 0.8 mmol/L (Fig. 5A ). After achieved equilibrium between the two compartments by medium circulation began, the concentration level in the 28 h and ammonium and glucose by 20 h. Thus, the inner circuit (HepG2 site) was maintained around 0.8 passive diffusion rate, P, was calculated from the time mmol/L throughout the circulation period. On the other needed for the difference in metabolite concentration behand, the concentration in the outer circuit (PCTL site) tween the two compartments to be reduced by half, t 1/2 ; increased steadily and reached 11.0 mmol/L at the end the surface area of the membrane, S; and the volume of of the 7 days. reservoir, V; using the following equation: P = ln(1/2) ×
The ammonium concentration in the outer circulation V/S × t 1/2 . It was calculated to be 5.1 × 10 −4 , 5.0 × 10 −5 , was virtually unchanged and the level was maintained and 8.5 × 10 −5 cm/s, respectively, for lactate, ammonia, at between 4 and 5 mg/dl (mean ± SD, 4.35 ± 0.22 mg/ and glucose. dl) (Fig. 5B ). In contrast, the level in the inner circula-Cell-Mediated Metabolism and Transport tion medium decreased steadily from 4.6 mgN/dl to 2.7 mgN/dl during the 7 days. When 1.0 × 10 8 PCTL-MDR cells were seeded on the outer side of the ePTFE membrane, a tight monolayer
The concentration of glucose in the outer circuit decreased steadily during the 7 days of circulation from was formed in 3 days. Fresh growth medium was replenished in the circulation units, and the concentrations of 3.0 mg/L to 2.0 mg/L, while it was maintained in the inner circuit at approximately 3.2 mg/L (Fig. 5C ). lactate ions, glucose, and ammonium ions were deter- partment side of its separation membrane. medium (B), or PBS (C) were circulated, respectively. A sample (5 ml) was removed from a reservoir bottle containing 500 ml solution every 4 h for chemical determination. In all experiments, perfusion rate was 10 ml/min. In this experiment, no cells were inoculated.
Lidocaine Detoxification and Transportation
cells was inoculated into the inner compartment as described in Materials and Methods. After further incuba-Before studying metabolism and transmembrane transtion for 6 days, lidocaine was added into the inner reserport of lidocaine in the DCCA, a dish-scale experiment voir bottle, at a final concentration of 100 µmol/L. The was performed. Nine 10-cm dishes, each containing 20 whole cell culture system was further incubated for 24 ml growth medium, seeded with GS-3A4-HepG2 cells, h. Thereafter, the deethylated metabolite of lidocaine, and with lidocaine added at a final concentration of 100 MEGX, as well as lidocaine itself, was detected in both µmol/L, were incubated and harvested at 12-h intervals compartments, although only approximately 1% of lidoover a total period of 96 h. As shown in an HPLC profile caine was metabolized to MEGX in this experiment, as of a sample obtained during the incubation (Fig. 6) , lidoshown in Table 1 . caine and its major metabolite MEGX were clearly separated from each other.
DISCUSSION The identity of the latter peak with MEGX was con-
The DCCA described here has several advantageous firmed using an authentic sample of MEGX. Approxifeatures as an experimental culture model; for instance, mately one third of the lidocaine added was metabolized simple assembly, ease of changing the membrane and during the 96-h period, and approximately 70% of the other materials, and feasibility of inoculating two differmetabolites recovered was MEGX. ent types of cells on the opposite sides of the membrane. To study the metabolism and transmembrane trans-Previously, using a small-scale static culture, we report of lidocaine in the DCCA, a suspension containing ported that the coculture of hepatic and renal cells on an 1.0 × 10 8 PCTL-MDR cells was inoculated into the outer ePTFE membrane facilitated the metabolism and onecompartment of the apparatus, which was then incubated way transport of testosterone. In the small-scale system, for 24 h to allow formation of a cell sheet on the ePTFE 4 × 10 6 cells were inoculated on either side of the 3.14membrane. Next, the same number of GS-3A4-HepG2 cm 2 membrane (5,6). Here the DCCA was able to maintain approximately 25 times more cells constantly circulating in the culture medium than in the previous static culture unit. We believe that this device may be suitable for preclinical animal experimentation. The ePTFE membrane has been used for industrial purification of water and for artificial blood vessels in the medical field. In spite of its hydrophobicity, the membrane was suitable as a cell culture substrate (18) . The merits of ePTFE membrane as a culture substrate include heat stability, chemical inertness, and mechanical strength. Thus, we believe that ePTFE is one of the best choices as a culture substrate for the DCCA, among all candidate materials, such as polysulfone, polyamide, centration 100 µmol/L), and then the system was incubated for 24 h before sampling for HPLC.
Peak A is lidocaine, B is phenol red, and C is MEGX. polyacrylonitrile (PAN), or polymethyl methacrylate However, unbound bilirubin was highly toxic to the cells in our model, even at a concentration within its physio-(PMMA) membranes.
Renal proximal cells are known to form a tight mono-logical range. To render cells resistant to bilirubin, transduction of UDP-glucuronosyl transferase should be ef-layer barrier on a synthetic membrane (5, 6, 8, 10, 19) . Our previous work showed that the monolayer of PCTL-fective. We have started to develop HepG2 transduced with this transferase, and to construct a DCCA that will MDR selectively passed digoxin, a typical substrate of anion transporter, MDR1, but did not pass inulin (5). In possess bilirubin removal activity. the present study, we confirmed selective transport by increased while in the inner compartment; the levels of these two substances were unchanged. This suggests that REFERENCES the cell layer efficiently prevented cross-membrane pas- ing activity of liver and is metabolized to MEGX by
